N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 21.6 NOK Market Closed
Market Cap: 381.5m NOK

EV/EBIT
Enterprise Value to EBIT

11.5
Current
15.9
Median
15.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
11.5
=
Enterprise Value
415.7m NOK
/
EBIT
36.1m NOK
Market Cap EV/EBIT
NO
Navamedic ASA
OSE:NAVA
381.5m NOK 11.5
US
Eli Lilly and Co
NYSE:LLY
753.7B USD 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.7B USD 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 14.5
CH
Roche Holding AG
SIX:ROG
208.9B CHF 11.1
CH
Novartis AG
SIX:NOVN
188.5B CHF 14.4
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP 196.9
US
Merck & Co Inc
NYSE:MRK
198.3B USD 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
137.5B USD 10.5
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 698.4
11.5
33%
0.3
US
Eli Lilly and Co
NYSE:LLY
39.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
14%
1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
196.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1.1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
10.7
2-Years Forward
EV/EBIT
7.1
3-Years Forward
EV/EBIT
5.5